Table 4.
CMR characteristics of patients and controls
| Unit | SBMA cohort, n = 30 | Control cohort, n = 11 | Unpaired t-test p-value | |
|---|---|---|---|---|
| LVEF (%) | Mean ± SD | 66.00 ± 4.95 | 64.40 ± 7.56 | 0.25 |
| LVEDV index (ml/m2) | Mean ± SD | 61.66 ± 14.67 | 79.10 ± 15.45 | 0.0008 |
| RVEF (%) | Mean ± SD | 64.13 ± 7.21 | 57.20 ± 6.11 | 0.007 |
| RVEDV Index (ml/m2) | Mean ± SD | 64.35 ± 16.42 | 75.30 ± 17.49 | 0.05 |
| Hypertrophy n, (%) | Frequency | 10/29 (34) | 2/10 (20) | 0.41 |
| RV dilatation n, (%) | Frequency | 1 (3) | 0 (0) | 0.56 |
| T1 MAP nativ (ms) | Mean ± SD | 1055 ± 51.5 | 992.9 ± 30.5 | 0.001 |
| T1 path overall n, (%) | Frequency | 17/23 (73.9) | 1/10 (10) | 0.0004 |
| T2 path overall n, (%) | Frequency | 2/29 (7) | 0 (0) | 0.41 |
| LVEF < 55% n, (%) | Frequency | 0 (0) | 0 (0) | - |
| Presence of LGE n, (%) | Frequency | 0 | 0 | - |
| Any CMR abnormality and any repolarization disturbances in ECG (Brugada/J-wave/fQRS) | Frequency | 14/25 (56) | - | - |
CMR indexes related to body surface areas (BSA), which was calculated by the Dubois and Dubois regression formula BSA = 0.007184 × weight(Kg)0.425 × height[cm]0.725
LVEF left-ventricular ejection fraction, LVEDVI left-ventricular end-diastolic volume index, RVEF right-ventricular ejection fraction, RVEDVI right-ventricular end-diastolic volume index, SBMA spinobulbar muscular atrophy